India's Richest People 2019 edition · Source: Hurun India
Rank#819- Wealth
- ₹1,000 Cr
- Company
- Laborate Pharmaceuticals
Aditya Bhatia
Active Director Director DIN 00038893
Unlock full profile Investments · shareholding · contact details
Current companies 4 active board seats
Past companies 1 historical roles
Total affiliations 5 Since Apr 2004
Shareholding value •••• Premium profile
About Aditya Bhatia
Data last updated:
Aditya Bhatia is a Director at Medcell Pharma Private Limited (since 2022), Director at Zypher Lifesciences Private Limited (since 2007) and Designated Partner at Zenith Zone Developers Llp (since 2025), and holds 1 more current directorship. The companies operate in Pharma and Chemicals. The 2 current companies with reported revenue have a combined latest revenue of ₹65.18 Cr; the largest is Medcell Pharma Private Limited at ₹63.46 Cr (FY 2025). Earlier, Aditya Bhatia was a Whole-Time Director at Laborate Pharmaceuticals India Ltd (2004–2021).
Aditya Bhatia was among India's richest people in 2019 at #819.
DIN 00038893
Primary Designation Director
Industry Pharma
First Appointment 01 Apr 2004
Oldest Company Age 19 yrs
Largest company Medcell Pharma Private Limited · ₹63.46 Cr (FY 2025)
Combined revenue ₹65.18 Cr across 2 companies
Recognitions & Rankings
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
 Medcell Pharma Private Limited U24230HR2022PTC106564 | Director | 13 Sep 2022 | 2022 | ₹63.46 Cr (FY 2025) | Active |
| Zypher Lifesciences Private Limited U29297DL2007PTC160681 | Director | 19 Mar 2007 | 2007 | ₹1.72 Cr (FY 2025) | Active |
| Zenith Zone Developers Llp ACM-6600 | Designated Partner | 13 Mar 2025 | 2025 | Active | |
| Ruxall Vita Private Limited U24100DL2021PTC382888 | Director | 29 Jun 2021 | 2021 | Active |
Previous companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
 Laborate Pharmaceuticals India Ltd U24239HR1990PLC030835 | Whole-Time Director | 01 Apr 2004 | 1990 | ₹1,553 Cr (FY 2025) | Active |
Explore Director's current and past company associations Uncover their professional journey today!
Board colleagues of Aditya Bhatia
| Name | DIN | Company | Designation |
|---|---|---|---|
| Anita Bhatia | 00038907 | Medcell Pharma Private Limited , Zypher Lifesciences Private Limited and 1 more | Director |
| Gunjan Bhatia | 08960766 | Medcell Pharma Private Limited , Zypher Lifesciences Private Limited and 2 more | Director |
Directorship timeline
Open interactive timeline →Ruxall Vita Private Limited
Medcell Pharma Private Limited
Zypher Lifesciences Private Limited
Zenith Zone Developers Llp
Premium access
Shareholding and investment profile for Aditya Bhatia
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Aditya Bhatia
Aditya Bhatia currently holds 4 directorships: Medcell Pharma Private Limited (Director, since 13 Sep 2022, revenue ₹63.46 Cr (FY 2025)); Zypher Lifesciences Private Limited (Director, since 19 Mar 2007, revenue ₹1.72 Cr (FY 2025)); Zenith Zone Developers Llp (Designated Partner, since 13 Mar 2025); Ruxall Vita Private Limited (Director, since 29 Jun 2021).
Aditya Bhatia was first appointed on 01 Apr 2004 as Whole-Time Director at Laborate Pharmaceuticals India Ltd. The most recent appointment on record is 13 Mar 2025 at Zenith Zone Developers Llp.
The 2 current companies of Aditya Bhatia that report revenue have a combined latest revenue of ₹65.18 Cr: Medcell Pharma Private Limited ₹63.46 Cr (FY 2025); Zypher Lifesciences Private Limited ₹1.72 Cr (FY 2025).
Aditya Bhatia held 1 earlier board appointment: Laborate Pharmaceuticals India Ltd (Whole-Time Director, 01 Apr 2004 to 04 Jan 2021).
The current boards of Aditya Bhatia's companies include Anita Bhatia (Medcell Pharma Private Limited), Gunjan Bhatia (Medcell Pharma Private Limited).